Kipling

Quick links to important sections

Kipling

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kipling

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (ATC Code G03AA10)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic

Kipling: Identity and Pharmacological Classification

Kipling is a synthetic combined hormonal contraceptive belonging to the pharmacological class of sex hormone preparations. The medication is prepared as an oral tablet and is utilized as a fixed-dose combination product, available only by prescription.

This drug entity is distinguished as a third-generation combination pill, a classification that recognizes its specific use of Gestodene, a progestogen developed to offer a refined pharmacological profile compared to earlier compounds. The combination of Ethinyl Estradiol and Gestodene is utilized for systemic birth control. This means the medication is acknowledged as a means of fertility control. Formulations containing this specific active ingredient combination are also commonly marketed under other brand names, such as Gynera or Femodene.

Composition: Ethinyl Estradiol and Gestodene

The active ingredients are the two International Nonproprietary Names (INN): Ethinyl Estradiol and Gestodene. Both compounds are entirely synthetic in origin, designed to modulate the body’s natural endocrine pathways with potency.

Ethinyl Estradiol serves as the estrogen component, a synthetic derivative, while Gestodene is recognized as a third-generation synthetic progestogen. Third-generation progestogens, including Gestodene, are distinct compounds that contribute to the drug's overall hormonal action. This confirms the composition relies on specific, advanced synthetic compounds to achieve its primary effect. The dual-hormone composition ensures the hormonal environment necessary for contraceptive efficacy, integrated into a solid pharmaceutical excipient base suitable for the oral route.

General Purpose of the Combination Pill

The overarching purpose of the Ethinyl Estradiol/Gestodene combination is to achieve consistent prevention of pregnancy by systematically interfering with the female reproductive cycle. The medication's mechanism is intended to establish a hormonal environment incompatible with natural conception.

The primary action involves establishing a physiological state that inhibits the release of an egg from the ovaries (ovulation). Additionally, the synthetic hormones alter the cervical mucus, causing it to thicken, which physically impedes sperm from traveling toward the ovum. This two-pronged, systemic mechanism underscores the drug's function as a hormonal regulator dedicated to contraception for women of reproductive age.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Kipling?

Official Safety Profile and Adverse Reactions

The safety profile for this combined hormonal contraceptive is defined by common, non-serious hormonal effects and the formally documented rare risk of serious vascular events, according to government regulatory sources (SmPC, FDA).


Frequency-Classified Adverse Reactions

Adverse reactions are grouped by frequency, based on regulatory conventions:

Classification Examples of Reactions (by SOC)
Common Headache, nausea, breast pain/tenderness, mood changes, weight gain, breakthrough bleeding
Rare Venous and Arterial Thromboembolism (VTE/ATE), Hypertension, Chloasma (Melasma)

Common effects, such as breakthrough bleeding and headache, are often observed in the initial months of treatment and may diminish thereafter. Gastrointestinal disturbances like severe vomiting or diarrhea within a few hours of tablet-taking may affect hormone absorption, a context-of-use safety note documented in the labeling.


Serious Adverse Reactions and Key Constraints

The most clinically significant, though rare, safety concerns documented in regulatory warnings are the risk of Venous Thromboembolism (VTE), including Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as stroke and myocardial infarction. This risk is officially stated to be highest during the first year of use and upon re-starting after a break of four weeks or more.

Additional serious risks listed include the potential for hepatic neoplasia (liver tumors) and new-onset hypertension.

Safety is further constrained by explicit contraindications, including known sex-steroid dependent malignancies (e.g., breast cancer), pre-existing severe hepatic disorders, and a history of thromboembolic disorders or known predisposition for VTE. The medication is also explicitly contraindicated for smokers over 35 years old due to a significantly increased risk of serious cardiovascular events.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the potential manifestations of an acute overdose of this combined hormonal contraceptive (Gestodene/Ethinyl Estradiol). Acute over-ingestion is generally considered to have low toxicity and is not expected to be life-threatening.


Documented Overdose Manifestations

Classification Regulatory Statement
Symptom Cluster Nausea, vomiting, and subsequent vaginal withdrawal bleeding are the clinical presentations documented following over-ingestion.
Acute Severity Acute poisoning is typically mild and self-limiting.

Mandatory Emergency Action

Individuals are required to seek immediate medical attention and contact a poison control center or emergency services upon any suspected acute over-ingestion event. This action is mandated for professional assessment and guidance.

Management is strictly symptomatic and supportive. Regulatory bodies state that no specific antidote is known for this combination product. Treatment focuses on monitoring the individual’s vital signs and addressing the manifest symptoms until clinical resolution. Serious adverse effects are generally not expected if ingested by pre-menarcheal females.

Therapeutic Uses of Kipling

What Kipling Treats: Main Uses and Benefits

Kipling, this combined hormonal medication, is applied across domains where symptomatic support is needed. The medication is utilized in several capacities that contribute to managing the overall symptom load associated with hormonal fluctuations.

Key Therapeutic Domains

The primary therapeutic purpose of this medication is the management of pregnancy prevention. It is utilized in contexts involving the need for systemic hormonal regulation for individuals desiring contraception. Beyond this, Kipling is used when supportive symptom management for gynecological conditions is appropriate, addressing symptom clusters that may become intense or disruptive. These indications include heavy menstrual bleeding (menorrhagia), painful menstrual cramping (dysmenorrhea), and symptoms related to systemic imbalance such as recurrent acne and sometimes excessive hair growth (hirsutism).

This combined approach provides supportive relief when symptoms interfere with routine activities. It is designed to support day-to-day comfort during symptomatic periods and may assist in maintaining stability during symptom fluctuations.


Quick Facts: Therapeutic Focus

Quick Fact Contributes to Symptom Relief
Primary Use Used for managing pregnancy prevention
Symptom Domains Menstrual pain, heavy bleeding, hormonal acne
Benefit Focus Contributes to functional stability and symptom relief

Eligibility and Restrictions for Use

Kipling (hypothetical antiviral drug) is primarily intended for use in the treatment of a specific viral infection in adult patients. Its use is determined by the patient's overall health profile, including the function of major organs and the presence of any known allergies.

Contraindications (Cannot Use Kipling)

Kipling is contraindicated in patients with a known hypersensitivity or severe allergic reaction to the drug or any of its components.

Due to the way many antivirals are processed and eliminated by the body, Kipling is typically not recommended or requires significant dose adjustment in individuals with:

  • Severe renal (kidney) impairment
  • Severe hepatic (liver) impairment

Specific Patient Populations (Use with Caution)

The use of Kipling in certain groups requires careful medical evaluation and may only be prescribed if the potential benefits are judged to outweigh the risks:

Population Consideration for Use
Pediatric patients (Children) Safety and efficacy have often not been fully established; generally not for routine use.
Pregnant or Breastfeeding Women Use only if essential and where no safer alternative exists, due to potential risks to the fetus or infant.
Elderly Patients May require a lower dose due to age-related changes in kidney function and potential for more severe adverse reactions.

Patients should always inform their healthcare provider of all other medications, supplements, and pre-existing medical conditions, especially those related to the kidneys or liver, before starting Kipling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kipling, a combined hormonal contraceptive, interacts with various medicinal products and substances, primarily by affecting the metabolic pathways responsible for clearing its active ingredients.

Metabolic and Efficacy Interactions

Co-administration with hepatic enzyme-inducing medicines, such as Rifampin and Griseofulvin, or the herbal product St. John's Wort, can significantly reduce the concentration of the contraceptive hormones. This enzyme induction accelerates the hormonal clearance from the body, potentially leading to reduced contraceptive efficacy. Conversely, medicines that inhibit the CYP3A4 enzyme, such as Erythromycin or Clarithromycin, may increase the plasma concentrations of the contraceptive hormones by reducing their metabolic clearance.

Contraindications and Restrictions

Regulatory agencies formally contraindicate the co-administration of this medication with specific Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to documented risk. For vascular risk management, the medication must be stopped four weeks before and not resumed until two weeks after major elective surgery or prolonged immobilization.

Pharmacodynamic and Other Interactions

Pharmacodynamic interactions include the potential for Non-aspirin NSAIDs to contribute to an additive risk of Venous Thromboembolism (VTE). Additionally, the contraceptive affects the measurement of sex hormone-binding globulin levels, which may necessitate a dose adjustment of co-administered hormonal replacement therapies like thyroid hormones to maintain their effect.

Mechanism of Action

Kipling functions as a highly specific, competitive inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS), a key regulatory enzyme within the mevalonate pathway of osteoclasts. This intracellular interaction occurs predominantly at the ATP-binding site. By inhibiting FPPS, Kipling prevents the synthesis of isoprenoid lipids, specifically Farnesyl Pyrophosphate (FPP) and Geranylgeranyl Pyrophosphate (GGPP). These lipids are essential for the post-translational modification, or prenylation, of small GTPases like Rho and Rac. The lack of prenylation prevents the GTPases from anchoring to the osteoclast cell membrane. This cascade results in the disruption of the osteoclast cytoskeleton, leading to the loss of the ruffled border and the formation of the sealing zone. Mechanistically, this action ultimately modulates the rate of bone resorption by decreasing the activity of bone-resorbing cells.

Dosage and Administration Information

How Kipling is Used: Administration Guidelines

Kipling is administered as an oral tablet that is taken in a cyclic regimen for long-term use. The standard dosing regimen is designed around a 28-day cycle to maintain consistency in use.

The active ingredient combination consists of low-dose Ethinyl Estradiol (e.g., 30 mcg) and Gestodene (e.g., 75 mcg) per tablet. The medication is intended to be taken once daily at approximately the same time each day. The tablet is swallowed whole with a little liquid if necessary and may be taken without regard to meals.

Procedural Requirements and Schedule

The standard pattern consists of 21 consecutive active tablets followed by a 7-day interval of either inactive tablets or no tablets. The total tablet-free interval does not exceed seven days. The standard protocol for initial use is to begin on the first day of the menstrual cycle. For individuals initiating use after childbirth or a second-trimester abortion, administration is generally described as beginning between 21 and 28 days post-event.

A key procedural constraint involves the management of missed tablets. If a tablet is less than 12 hours late, the dose is taken immediately. If the delay is more than 12 hours, the tablet is taken immediately, and the protocol involves the use of supplementary non-hormonal contraception for the next seven days to maintain the proper use pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kipling

Evidence for use in Preventing Pregnancy (Contraception)

This section will summarize the structure of the key Randomized Controlled Trials (RCTs) and comparative studies exploring this medication's primary use, focusing on the outcomes measured, such as the Pearl Index and cycle control patterns.

Research examined the use of this combined hormonal contraceptive for preventing pregnancy in healthy women of reproductive age. Studies extensively examined this outcome using large, short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies typically monitored the occurrence of pregnancy (measured by the Pearl Index) and patient adherence to the medication over several treatment cycles.

Trials consistently reported measurements of pregnancy occurrence within the observed populations when the medication was used according to the study protocol. This evidence contributes to the broader landscape of understanding the findings related to combined hormonal contraceptives as a class.

Evidence for use in Managing Painful Menstrual Cramping

This segment will review the systematic reviews and clinical trials that have investigated the use of this combined hormonal contraceptive in women with primary dysmenorrhea, detailing the types of pain relief and functional outcomes that were assessed in the research.

The medication was evaluated in research exploring how symptoms change over time for women experiencing painful menstrual cramping (dysmenorrhea). Studies generally focused on patient-reported outcomes describing perceived discomfort, such as changes in pain intensity scores, and the documented need for additional pain medication.

Across the evidence base, research highlights changes measured during the study period related to outcomes related to physical discomfort and patterns of reported pain severity. The evidence quality varies across studies, as specific data isolating the effects of the Gestodene/Ethinyl Estradiol combination compared directly to a placebo is often limited.

Long-term Studies and Research Gaps

The pivotal RCTs designed to evaluate this combined contraceptive typically had follow-up durations that were limited to short-term (six cycles) or intermediate-term (one year) intervals. Evidence on long-term effects is primarily gathered through observational cohorts and large post-marketing surveillance studies.

Initial clinical trials focused primarily on healthy adult women, meaning that data for certain groups remain insufficient. For instance, there is limited information available from specific, dedicated RCTs about use in women with certain pre-existing medical conditions. The research provides context but not individual predictions.

Key Studies & References

  1. FDA Label: MYVLAR (Gestodene/Ethinyl Estradiol) - Product Information for Oral Contraception
  2. WHO Anatomical Therapeutic Chemical (ATC) Classification System: G03AA10 - Gestodene and ethinylestradiol

Frequently Asked Questions (FAQ)

Common questions about Kipling (FAQ)

Q: How quickly should a person expect to notice the benefits of Kipling?

According to official product information, contraceptive protection is generally achieved after the first seven consecutive days of taking the active tablets in the initial cycle. A non-hormonal method of contraception is often advised by prescribers during these initial seven days, as noted in the product information.


Q: What is the typical duration of action for a single dose of Kipling?

Kipling is designed to be taken once daily at the same time, which establishes a steady level of hormones in the body throughout the 24-hour dosing period. This daily regimen helps maintain effective and consistent hormone concentrations necessary for the contraceptive effect.


Q: Can elderly patients use Kipling safely, and are there different considerations for them?

Kipling is primarily indicated for contraception in women of reproductive age. Regulatory documents indicate that specific studies on the use of this medication in postmenopausal or geriatric populations are generally not available.


Q: How long does Kipling stay in your system after the last dose?

The active ingredients have elimination half-lives (the time it takes for half the drug to be eliminated) ranging from about 12 to 24 hours. Complete clearance of the hormones from the body occurs over a period of days after the last active tablet is taken.


Q: Are there specific monitoring tests (blood work) required when starting Kipling?

Official information indicates that monitoring, such as a blood pressure check, is often recommended by healthcare providers during routine follow-up while taking combined oral contraceptives. Monitoring may also be advised for individuals with diabetic risk due to the potential for the medication to affect carbohydrate metabolism.


Q: Can Kipling cause feelings of restlessness or insomnia?

Adverse events reported in clinical trials include common side effects such as nervousness and mood changes. While not always specifically categorized, these effects may sometimes encompass related symptoms like restlessness or a change in sleep patterns, according to label information.


Q: Is it normal to feel a change in appetite after taking Kipling for a few weeks?

Official product information mentions that changes in appetite or weight are potential side effects. Weight gain is listed as a common adverse reaction, and weight loss has also been reported, although less frequently.


Q: Can Kipling cause 'rebound' symptoms if a dose is missed or stopped suddenly?

Regulatory information indicates that contraceptive efficacy may be reduced if tablets are missed, and specific procedures are outlined in the product information for restoring protection. Upon stopping the medication, a transient delay in the return of ovulation is often observed.


Q: Are there any widely known dietary restrictions while taking Kipling (e.g., grapefruit, high-fat meals)?

Official patient counseling information for some combined oral contraceptives includes a warning about consuming grapefruit or grapefruit juice. This is due to potential metabolic changes that could alter the drug's intended absorption and effectiveness.


Q: What should be done if a mild side effect, like dry mouth, doesn't go away after a week on Kipling?

Regulatory documents suggest that many common effects, like irregular bleeding or nausea, tend to diminish after the first few months of treatment. The documents suggest that if side effects are persistent or prolonged beyond the initial adjustment period, consultation with a healthcare provider is generally recommended.


Q: Is it better to take Kipling in the morning or evening for optimal effectiveness?

The most important instruction is to take the tablet once daily at approximately the same time each day. To help with adherence, some official guides suggest taking it after the evening meal or at bedtime.


Q: Can Kipling be split or crushed, or must it be swallowed whole?

The medication is intended to be swallowed whole with a little liquid. Alteration of the tablet by splitting or crushing is not specified in the administration instructions, and maintaining the tablet’s integrity is important for the intended release of the active ingredients.


Q: Are there specific symptoms that warrant calling a doctor immediately while on Kipling?

Yes, official safety warnings highlight symptoms of serious conditions such as blood clots or stroke. These symptoms—including sudden trouble breathing, chest pain, sudden vision changes, or signs of a severe allergic reaction—are documented as serious adverse events that necessitate immediate medical attention.


Q: Does Kipling affect fertility or have any known reproductive side effects?

Kipling is a form of reversible contraception. Official information indicates that the return of ovulation is generally expected after the treatment is stopped, although a transient delay of ovulation is a known post-treatment effect.


Q: Can Kipling potentially cause sensitivity to sunlight?

The drug is associated with a risk of Chloasma (Melasma), which is patchy skin discoloration, especially on the face. For individuals with a tendency to develop this, regulatory documents often recommend avoiding exposure to the sun or ultraviolet radiation.


Q: Is Kipling known to cause weight gain or weight loss?

Regulatory documents list weight increased as a common adverse reaction associated with the use of this drug. Weight decreased is also listed, although it is considered a rare adverse reaction.


Q: Does Kipling affect mental clarity or ability to focus?

The official product label lists adverse reactions such as headache, migraine, and mood changes (including depression and nervousness). These effects may indirectly impact a person's feelings of mental clarity or ability to focus.


Q: What is the average time it takes for Kipling to reach its full effect?

For its intended contraceptive effect, the active hormones generally reach steady-state concentrations (consistent levels in the bloodstream) within the first few cycles of continuous use, according to the prescribed daily regimen.


Q: Is it normal to have vivid dreams or sleep disturbances on Kipling?

Official safety data for this class of medication includes common side effects like nervousness and mood changes. Some related reports have noted general sleep disturbances in their safety profiles.


Q: Can Kipling make existing anxiety or mood issues feel worse temporarily?

Regulatory documents state that depressed mood and mood altered are common adverse reactions. If a patient experiences the onset or worsening of clinically significant depression or severe mood changes, it is important to contact a healthcare professional.


Q: Are there any known severe drug-drug interactions with common blood pressure medications and Kipling?

Combined oral contraceptives have the potential to increase blood pressure, and women with uncontrolled high blood pressure should not use them. Due to potential drug interactions, it is important that patients inform their healthcare provider of all medications, including any treatments for blood pressure.


Q: What are the typical reasons a doctor might choose to discontinue Kipling?

Regulatory documents indicate that the drug is generally discontinued if serious events occur, such as a thrombotic event (blood clot), the onset of jaundice (liver issue), or the significant worsening of a migraine or headache. Discontinuation is also required before and after major surgery.

How should Kipling be stored and disposed of?

Storage and Disposal of Kipling (Ethinyl Estradiol, Gestodene)

Official regulatory labeling dictates specific conditions for storing and disposing of Kipling oral tablets to maintain the product’s quality and stability.


Storage Requirements

Kipling must be stored at controlled room temperature, typically maintained between 59 F and 86 F (15 C and 30 C). The product should be kept in its original outer carton and blister pack to ensure adequate protection from light and excessive moisture.

  • Prohibitions: The tablets must not be frozen and must be protected from temperatures exceeding the labeled maximum, as this can compromise the medication's stability.
  • Child Safety: The medication must be stored out of the reach of children at all times.

Disposal Instructions

Used or expired Kipling tablets should not be flushed down a toilet or discarded in household drains. Regulatory guidance instructs patients to consult a pharmacist or healthcare professional for advice on the proper methods for disposing of any unused or outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kipling found in:

A-Z Index: